Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
6,140
Employees6,140
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
6,140
Employees6,140

NTRA Key Statistics

Market cap
40.00B
Market cap40.00B
Price-Earnings ratio
-170.18
Price-Earnings ratio-170.18
Dividend yield
Dividend yield
Average volume
2.14M
Average volume2.14M
High today
$279.63
High today$279.63
Low today
$271.64
Low today$271.64
Open price
$278.47
Open price$278.47
Volume
1.27M
Volume1.27M
52 Week high
$279.63
52 Week high$279.63
52 Week low
$131.81
52 Week low$131.81

Stock Snapshot

Natera(NTRA) stock is priced at $279.32, giving the company a market capitalization of 40B. It carries a P/E multiple of -170.18.

As of 2026-07-05, Natera(NTRA) stock has fluctuated between $271.64 and $279.63. The current price stands at $279.32, placing the stock +2.8% above today's low and -0.1% off the high.

The Natera(NTRA)'s current trading volume is 1.27M, compared to an average daily volume of 2.14M.

During the past year, Natera(NTRA) stock moved between $131.81 at its lowest and $279.63 at its peak.

During the past year, Natera(NTRA) stock moved between $131.81 at its lowest and $279.63 at its peak.

NTRA News

Simply Wall St 2d
Natera Lands New Trial Partnerships, Is The Upside Already Priced In?

Natera (NTRA) has drawn fresh investor attention after a series of partnerships and approvals, including new Phase 3 trial collaborations and regulatory clearan...

Natera Lands New Trial Partnerships, Is The Upside Already Priced In?
Nasdaq 6d
Natera Partners With Aveta Biomics On Phase 3 Head And Neck Cancer Trial

(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company, and Aveta Biomics, Inc., an immuno-oncology company, on Monday announced a partnership to s...

Natera Partners With Aveta Biomics On Phase 3 Head And Neck Cancer Trial
Simply Wall St 6d
Exploring 3 High Growth Tech Stocks in the US Market

Over the last 7 days, the United States market has experienced a 2.5% drop, yet it remains up by 19% over the past year with earnings forecasted to grow by 18%...

Exploring 3 High Growth Tech Stocks in the US Market

Analyst ratings

88%

of 24 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

More NTRA News

TipRanks 6d
Natera price target raised to $290 from $270 at Guggenheim

Guggenheim analyst Subbu Nambi raised the firm’s price target on Natera (NTRA) to $290 from $270 and keeps a Buy rating on the shares. The firm adjusted models...

TipRanks 6d
Natera, Aveta Biomics announce strategic partnership

Natera (NTRA) and Aveta Biomics announced a strategic partnership supporting AVTA 30-01, Aveta’s global Phase 3 registrational clinical trial evaluating APG-157...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.